We are using electric cell-substrate impedance sensing (ECIS) and confocal microscopy, as well as other assays, to observe and quantify endothelial cell damage after exposure to non-identical ABO type plasma in vitro. This involves the generation of ABO immune complexes by mixing concentrated O and A plasmas together, the effects of which mimic ABO non-identical transfusion in vivo.
Learn more about ABO Immune Complexes Cause Endothelial Cell Damage
We obtained a patent for developing a new, procoagulable, platelet lysate product to be potentially administered topically for bleeds in both trauma and surgical settings. We are using thromboelastography (TEG), platelet and whole blood aggregation studies, thrombin generation assay (TGA), as well as flow cytometry to evaluate our product’s effectiveness compared to standard platelet products.
Learn more about Platelet Lysate (PL) Product As a New Means For Topical Application in Wounds
We are investigating new means for the diagnosis of heparin induced thrombocytopenia (HIT), an immune-mediated response to long-term heparin therapy. This project involves the use of flow cytometry of platelets in order to determine whether some patients are biologically more susceptible to HIT than others via differences in platelet membrane receptors.
Learn more about HIT: Why Are Some Patients More Susceptible Than Others?